Previous close | 0.3000 |
Open | 0.3000 |
Bid | 0.4000 |
Ask | 0.5500 |
Strike | 50.00 |
Expiry date | 2024-07-19 |
Day's range | 0.3000 - 0.3000 |
Contract range | N/A |
Volume | |
Open interest | 8.34k |
NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted diluted EPS to $2.14 CER, has started discussions with NeuMoDx customers to assess impact on 2024 sales // Restructuring charge of approximately $400 million – including about $300 million of non-cash charges – planned to be recognized primarily in 2024Venlo, the Netherlands, June 06, 2024 (GLOBE NEWSW
New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers’ customization needs, complementing QIAGEN’s existing pre-designed assays // GeneGlobe Design and Analysis Hub receives further enhancements, improving user experience and capabilities to design panels collaboratively // Advancements strengthen QIAGEN as a trusted partner for researchers, catering to their diverse needs to further accelerate drug discovery and other applicationsVenlo, the Ne
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.